![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
782kB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supplementary Material)
257kB |
| Item Type: | Review |
|---|---|
| Title: | Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency |
| Creators Name: | Cowan, J., Na, I.K., Gladiator, A., Kamieniak, M. and Mustafa, S.S. |
| Abstract: | Subcutaneous (SCIG) and intravenous immunoglobulin (IVIG) replacement are both used to prevent infections in patients with secondary immunodeficiency (SID). Compared with IVIG, SCIG has fewer systemic side effects and, additionally, facilitates home-based treatment. Shared decision-making practice should include discussion of aspects such as patient preference as well as the associated risks and benefits of treatment. We review the available evidence for the use of SCIG treatment in patients with SID, focusing on patient-reported outcomes (PROs). In most studies, there were improvements to health-related quality of life with SCIG treatment, compared with before initiating SCIG without prior IVIG treatment, or after switching to SCIG from IVIG treatment, or a no-SCIG/IVIG cohort. Treatment satisfaction with SCIG was similar between patients with SID and primary immunodeficiency disease. Patient preference and perception assessments highlighted the benefits of SCIG compared with IVIG, such as ease of use and administration, convenience, and time-effectiveness. In addition, many patients self-administered SCIG at home. Such aspects may be of specific benefit to patients with SID and hematological malignancy by reducing the risk of infection exposure in clinical settings. PRO data may be useful during shared decision-making discussions with patients with SID. |
| Keywords: | Secondary Immunodeficiency, Hematological Malignancy, Subcutaneous Immunoglobulin, Patient-Reported Outcomes, Health-Related Quality Of Life, Treatment Satisfaction, Patient Preference, Shared Decision-Making |
| Source: | Frontiers in Immunology |
| ISSN: | 1664-3224 |
| Publisher: | Frontiers Media SA |
| Volume: | 16 |
| Page Range: | 1528414 |
| Date: | 20 March 2025 |
| Official Publication: | https://doi.org/10.3389/fimmu.2025.1528414 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
